Elizabeth A. Gasser - 03 Nov 2021 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role: EVP, Chief Strategy Officer
Signature: s/ David B. Berger, Attorney-in-Fact for Elizabeth A. Gasser
Issuer symbol: TNDM
Transactions as of: 03 Nov 2021
Net transactions value: +$606,062
Form type: 4
Filing time: 05 Nov 2021, 16:59:57 UTC
Previous filing: 31 Aug 2021
Next filing: 01 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNDM	Common Stock	Options Exercise	$1,426,909	+15,936	+1308%	$89.54	17,154	03 Nov 2021	Direct	F1
transaction	TNDM	Common Stock	Options Exercise	$401,325	+4,874	+28%	$82.34	22,028	03 Nov 2021	Direct	F1
transaction	TNDM	Common Stock	Sale	$3,050,408	-21,785	-99%	$140.02	243	03 Nov 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNDM	Stock Option	Options Exercise	$1,426,909	+15,936	+250%	$89.54	22,311	03 Nov 2021	Common Stock	15,936	$89.54	Direct	F4, F5
transaction	TNDM	Stock Option	Options Exercise	$401,325	+4,874	+121%	$82.34	8,887	03 Nov 2021	Common Stock	4,874	$82.34	Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon exercise of a stock option award.
F2	The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2021.
F3	The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $140.00 to $140.18. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F4	The options vested as to twenty-five (25%) of the underlying shares on 2/18/2021, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F5	The expiration date for these options is 10 years from the date of grant.
F6	The options vested as to twenty-five (25%) of the underlying shares on 5/27/2021, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the 2013 Plan.